Marcadores inmunológicos de diabetes tipo 1: análisis de 4.164 perfiles en un centro de salud de Chile

Abstract

Analysis of 4,164 type 1 diabetes antibody profiles in a Chilean health centreBackground: Previous studies have assessed the role of Type 1 diabetes (DM1) antibodies as predictors of the natural history of disease. Aim: To determine the frequency and combinations of positivity for DM1 antibodies in patients with DM1 and the relationship between antibody positivity and the age of the patient. To explore the relationship between history of insulin therapy or diabetic ketoacidosis (DKA) at the onset of the disease with antibody positivity in a subsample. Material and Methods: Data was gathered from every sample processed for DM1 antibodies in our laboratory between January 2015 and September 2019. Medical records from 84 patients who tested positive for at least one antibody were revised to study the relationship between insulin therapy or DKA at the onset of the disease with antibody positivity. Results: Forty percent of DM1 antibody tests were positive. Among positive tests, 1, 2, 3 or 4 DM1 antibodies were detected in 48%, 33%, 17% and 3% of cases, respectively. The likelihood of testing positive was inversely related with age for ICA, GAD, IA-2, ZnT8 and directly proportional for IAA (β = -

New-Onset Diabetes Mellitus after COVID-19: Combined Effects of SARS-CoV-2 Variants, Molecular Mimicry, and m6A RNA Methylation

“…T1DM is an autoimmune disease associated with the destruction of beta pancreatic cells. During the disease, several autoantibodies are produced such as those directed against insulin, tyrosine phosphatase, glutamic acid anti-decarboxylase enzymes, and the zinc transport protein [55]. The presence of these autoantibodies in an individual's blood serum is an indication that the immune system is attacking the pancreatic beta cells that produce insulin [56,57].…”

Механізм Дії Та Особливості Застосування Холекальциферолу В Дітей Та Підлітків На Етапах Розвитку Цукрового Діабету 1-Го Типу

“…ЦД1 в людини може виникнути в будьякому віці, але найбільша ймовірність його розвитку спостерігається в пацієнтів до 30 років, головним чином у дітей та підлітків віком до 15 років. Багаторічне проспективне вивчення цієї проблеми на величезному клінічному матеріалі показало, що пік сероконверсії та експресії автоантитіл до ОЛ та виникнення ЦД1 найчастіше спостерігається в молодшому дитячому віці та в пубертаті [47][48][49].…”